

Press information 01 February 2007

Oasmia enters new business field, Animal Health

Oasmia Pharmaceutical will launch a new division, Animal Health, during March of this year. The division will focus on development and marketing of oncology products for companion animals where the market potential is estimated to be very large.

Cancer in companion animals has attracted great attention. Recently, there has been an interest from both veterinarians and owners in developing treatment methods for this disease. The number of animals has increased, and they also have a longer life-span on the average. The cancer risk increases substantially with ageing. Put together, this accounts for a very large market potential for companion animal oncology products.

After very positive signals from clinical studies, Oasmias management has decided to launch a new division within the company: Animal Health. The management expects the market will grow substantially worldwide the coming six to ten years. Oasmia's assortment and product portfolio is judged to be very competitive in this relatively new market. More information will be available during March.

Oasmia Pharmaceutical (publ) is a pharmaceutical company based on the latest concepts in bio-organic chemistry. The company idea is to improve treatment of serious conditions, with a focus on oncology. This is done through development of semi-synthesised substances to a new generation of effective pharmaceuticals for various areas of therapy. Oasmia is noted on the NGM Nordic MTF. More information is available at www.ngm.se or at www.oasmia.com.

For more information, please contact Britt-Marie Eriksson VP, tel: +46 18 50 54 40, e-mail: info@oasmia.com